Omeprazole in Pregnancy: Safety Data, Risks, and Clinical Guidance

Omeprazole (PPI) is categorized as FDA Pregnancy Category C (older) / no category (new labeling). Human data are reassuring but limited.

Available Evidence

  • Cohort studies (Scandinavian registries, >5000 exposures): No increased risk of major congenital malformations overall or cardiac defects specifically with first-trimester use.
  • Meta-analyses: No significant association with malformations, miscarriage, preterm birth, or low birth weight.
  • Animal data: High-dose omeprazole in rats caused embryo-fetal toxicity (reduced weight, skeletal variations) at maternally toxic doses. No teratogenicity at human-relevant exposures.

Clinical Recommendations

  • First-line for GERD in pregnancy: Lifestyle (head elevation, small meals, avoid triggers), then antacids/alginates, then sucralfate.
  • If inadequate: H2 blockers (famotidine, ranitidine — though ranitidine withdrawn) preferred before PPIs due to longer safety track record.
  • PPI indication: Erosive esophagitis, Barrett's, refractory symptoms. Omeprazole 20 mg daily is standard.
  • Breastfeeding: Low milk transfer (<0.1% dose); considered compatible (AAP).

Key Points

Do not stop PPI abruptly if indicated — rebound hypersecretion worsens symptoms. Discuss risk-benefit with OB/GYN. Untreated severe GERD risks aspiration, malnutrition, esophageal damage.

Pregnancy & Health - Related Articles